Recently, a recruitment post for volunteers to strengthen vaccination at Tongji University Affiliated Dongfang Hospital (hereinafter referred to as Shanghai Dongfang Hospital) has been circulated on the Internet, recruiting elderly people aged 60-80 who have been infected with the new crown and have been vaccinated , the subsidy amount is as high as 8,000 yuan, which will be distributed in 4 installments.
On July 27, a reporter from China Business News called Shanghai Dongfang Hospital to learn about the situation. A relevant person in charge of consulting the vaccine trial project confirmed that This is a clinical trial conducted by the hospital and needs to meet several requirements:
- First of all It is age, and it needs to be born before July 1962;
- Second, it needs to have a history of new crown infection, and the time of discharge from the hospital should not be less than 7 days;< /li>
- Thirdly, two or three doses of inactivated vaccine need to be received, and the last dose needs to be more than 6 months old.
- In addition, the elderly also need to be evaluated for underlying diseases, such as hypertension, diabetes, coronary heart disease, etc., as well as allergies.
“Those who meet the above conditions will be entered into the group after passing the screening. The patients were randomly assigned to the clinical group. The experimental group was boosted with Sri Lanka’s mRNA vaccine, and the control group was boosted with a single shot of inactivated vaccine. Follow-up for 3 months. “The above-mentioned personnel told the first financial reporter.
In addition, according to reports, 8,000 yuan is a pre-tax subsidy, which will be distributed in four installments. After the booster vaccination is completed, 2,000 yuan will be distributed. After the blood is drawn during the 3-month follow-up, it will be distributed in succession. The remaining part.
Relevant consultants told reporters: “It’s not the end of the vaccine, but it is necessary to guarantee about 6 visits to the hospital, on the 7th and 14th days after vaccination. , the 28th and 60th day follow-up visits to the hospital on time to draw blood, and the total amount of blood drawn is 350-400 ml.”
In response to the question of what to do if there are risks in clinical trials, The above-mentioned personnel told Yicai.com that the people participating in the trial need to go to the hospital to sign an informed consent form, and the doctor will inform the relevant risks and how to deal with the adverse events.
The hospital did not disclose how many subjects were recruited for the entire clinical trial, but said the clinical trial has been halfway through since it opened in June and is still recruiting subjects .
The reporter learned from the company that the above-mentioned clinical trial was initiated by the researchers of Shanghai Dongfang Hospital, but the hospital Fang did not disclose the specific responsible platform to the first financial reporter, and said that it would be informed in the informed consent form.
About who will pay the 8,000 yuan subsidy, the hospital said that the hospital will issue it to the trial participants after the process is completed, and it may take a while. According to the reporter’s understanding from relevant persons in the enterprise, the compensation for the inoculated persons will be borne by the enterprise.
Public information shows that Li Hangwen, founder, chairman and CEO of Sri Lanka Microbiology, is still a researcher of the translational medicine platform of Oriental Hospital. As early as January 2020, Dongfang Hospital released information that it cooperated with Siwei to develop mRNA vaccines.
In addition to Dongfang Hospital, the mRNA vaccine of Sri Lanka is also undergoing clinical trials in Zhongshan Hospital Affiliated to Fudan University, Xuhui District Central Hospital, etc., all of which are clinical trials initiated by researchers. Last month, Zhongshan Hospital released information that the hospital is recruiting subjects for a Phase I clinical exploratory study of Sri Lanka’s mRNA vaccine. Persons who have received two doses of the new crown inactivated vaccine.
As of now, China has not approved any new crown mRNA vaccine for marketing, strong>Including Sri Lanka Microorganism, CanSino, CSPC, Watson Bio, etc. are all conducting research and development of mRNA vaccines.
[Source: China Business News, News Square]
Disclaimer: The copyright of this article belongs to the original author. If the source is wrong or your legal rights are violated, you can contact us by email We get in touch and we will deal with it in a timely manner. Email address: [email protected]